FDGtwo — GMP Fit & Distinctive Engineering for Cyclotron Radiopharmacy

A cyclotron radiopharmacy runs under four overlapping rule-sets. The synthesizer is where chemistry meets the audit trail.

Annex 3 covers the radiopharmaceutical manufacture; Annex 11 covers the computerised system and audit trail; the AERB cyclotron-facility document covers Indian site licensing; and the European Pharmacopoeia monograph for Fludeoxyglucose (18F) injection covers what each released batch has to satisfy. The FDGtwo is the engineered envelope inside which the radiopharmacy executes the validated recipe. This page maps the FDGtwo feature set against each requirement with every row cited — then calls out the four engineering features that are genuinely distinctive against the single-vessel baseline.

The four rule-sets the synthesizer has to fit inside

Each card is a published standard or regulator document; each defines a separate compliance surface the F-18 synthesizer has to face.

Annex 3

Radiopharmaceutical manufacture

EU GMP Annex 3 governs the cyclotron + synthesis + QC chain. A closed automated synthesis cell may be operated at Grade C internally — the operator does not handle live intermediates. The synthesizer module sitting inside the cell is the engineered control that makes the closed-system status real.

EU Commission, EudraLex Vol. 4 Annex 3 (PIC/S PE 009 mirror).

Annex 11

Computerised systems & audit trail

In-force text governs validation, audit trails and ALCOA+ data integrity for the cyclotron-site computerised systems. The synthesizer's control PC, the recipe-editor GUI and the electronic batch record are one node of that estate. Annex 11 revision is in EMA consultation (2025).

EU Commission, EudraLex Vol. 4 Annex 11; EMA concept paper, 2025.

AERB 2017

Indian cyclotron facility licensing

AERB Regulatory Requirements & Guidelines for Medical Cyclotron Facility (2017) — Atomic Energy (Radiation Protection) Rules 2004 licensing path. Automated synthesis equipment inside a self-contained controlled area is an explicit expectation of the document.

AERB (India), 2017.

Ph. Eur.

Fludeoxyglucose (18F) monograph

The European Pharmacopoeia monograph defines what every released batch has to satisfy — radiochemical purity, chemical purity, residual solvents, sterility, endotoxin, half-life confirmation. The synthesizer sets the engineering envelope; each batch is released against the monograph.

European Pharmacopoeia, current edition.

Requirement → FDGtwo feature

Each row maps a specific requirement from the GMP / AERB / Pharm. Eur. stack onto a documented FDGtwo feature. Source for each map cited inline.

Closed-system synthesis with no operator contact (Annex 3)

Two closed glassy-carbon reaction vessels (11 mL each, RT–200 °C) with integrated air cooling. The reactive intermediates stay inside the vessel; the operator works through the GUI, not through the chemistry.

Source: FDGtwo product page — vessel specification.

Software-driven recipe with audit trail (Annex 11)

Proprietary GUI with customisable synthesis protocols, manual and automatic operation modes, user-defined synthesis variations. The recipe is editable but the run is logged — basis for an electronic batch record once the site integrates the GUI output into its LIMS.

Source: FDGtwo product page — software description.

In-process verification across the synthesis path (Annex 3 + Ph. Eur. evidence)

Six shielded radiation detectors monitor activity at multiple points across the synthesis line — basis for stage-by-stage entries on the batch record rather than a single end-of-run yield reading.

Source: FDGtwo product page — in-process monitoring spec.

Cross-contamination control between batches (Annex 3 cleaning)

Built-in 45-minute self-clean cycle. Combined with the two-vessel architecture, the workflow is: setup → batch 1 → batch 2 → self-clean — operator does not have to author or run a manual cleaning recipe between sessions.

Source: FDGtwo product page — self-cleaning system.

Multi-batch session under one validated setup

Two independent reaction-vessel sets — two [18F]FDG productions from one operator setup. Fewer manual setups per session means fewer aseptic-intervention windows for the operator to document and fewer points of variance per validated recipe.

Source: FDGtwo product page — "two independent sets of a single synthesis unit allow two [18F]FDG productions with one setup".

Engineering envelope for Ph. Eur. release attributes

Manufacturer-guaranteed radiochemical yield 65–85 % and radiochemical purity above 98 % set the engineering envelope. The site's in-house validation runs demonstrate that the operating recipe meets the monograph release criteria inside that envelope.

Source: FDGtwo product page — published RCY and purity spec.

Fits a Grade-C synthesis hot cell (AERB self-contained area + Annex 3)

Compact 42 × 50 × 48 cm footprint, ~25 kg, fits a 55 × 55 × 50 cm minimum hot-cell envelope — sized for a SYNT-class synthesis hot cell with the shielding and ventilation that takes the cell to Grade C. The synthesizer drops into the cell rather than needing a bespoke shielded build.

Source: FDGtwo dimensions; SYNT product page — Grade C synthesis cell envelope.

Multi-tracer chemistry on one validated platform

Beyond [18F]FDG, the module supports [18F]FMISO, [18F]FLT, [18F]FCh and other nucleophilic [18F] compounds — the radiopharmacy validates one platform once, then runs additional tracers as separate validated recipes on the same equipment.

Source: FDGtwo product page — chemistry list.

Four features that map cleanly onto GMP requirements

"Better" is read against the single-vessel, end-of-run-only-detection baseline that most routine F-18 synthesizers in cyclotron radiopharmacies still represent. Each of the four features below maps onto an Annex 3 / Annex 11 / Pharm. Eur. requirement in a way that single-vessel platforms have to address through extra manual procedure rather than through engineering. We deliberately avoid head-to-head "better than GE FASTlab / IBA Synthera / Sumitomo F300E" framing — those direct published comparisons are not in PubMed.

Two-vessel architecture

Two independent reaction-vessel sets in one module is the published distinctive feature. Most cyclotron-radiopharmacy F-18 synthesizers in routine use are single-vessel platforms — one operator setup yields one batch. FDGtwo splits that one-to-one mapping: one setup yields two consecutive batches without re-priming the chemistry.

GMP fit: Halves the manual setup overhead per session, which directly reduces the number of aseptic-intervention windows the operator has to document under Annex 3 cleaning expectations.

Source: FDGtwo product page — two-vessel architecture description.

Six in-process radiation detectors

Activity is measured at multiple defined points across the synthesis line rather than only at the end-of-run dispense. A low-yield batch can be traced to a stage (fluoride trapping, hydrolysis, purification) rather than being recorded as a single off-spec event.

GMP fit: Supports the Annex-3 + Ph. Eur. expectation that the batch record carries process verification, not just a final release reading.

Source: FDGtwo product page — in-process monitoring spec.

Basic + acid hydrolysis on the same module

Two hydrolysis chemistries on the same hardware: basic hydrolysis under 28 minutes, acid hydrolysis under 22 minutes. The site can validate either recipe — or both — without buying a second machine.

GMP fit: Most published [18F]FDG production methods use basic hydrolysis; acid hydrolysis is a faster option that some sites prefer when intermediate stability is the bottleneck.

Source: FDGtwo product page — basic / acid hydrolysis spec.

Built-in self-cleaning cycle

45-minute cleanup runs as a programmed step at end of session. Cleaning validation under Annex 3 is the radiopharmacy's job; an automated cleaning cycle reduces the variance between cleaning runs and shrinks the gap between the validated cleaning recipe and the day-to-day execution.

GMP fit: A documented, repeatable cleaning step is a stronger Annex-3 cleaning-validation artefact than an operator-authored manual recipe.

Source: FDGtwo product page — self-cleaning system.

What the synthesizer does not do for you

The GMP and AERB stack is a programme, not a piece of equipment. The FDGtwo gives you a compliant synthesis node; the radiopharmacy still owns the rest.

The site GMP recipe — written, validated and held by the radiopharmacy

Per-batch Pharm. Eur. release — radiochemical purity, residual solvents, endotoxin, sterility, half-life confirmation

LIMS / electronic batch record validation per Annex 11 + GAMP 5 — the synthesizer's GUI output is the input; LIMS integration is the operator's programme

Site-wide Contamination Control Strategy (CCS) under Annex 1 (which bears on the downstream dispensing step rather than the closed synthesizer)

Cleaning validation — establishing that the engineered self-clean recipe meets the residue / cross-contamination limits the site defines

AERB site licence under the Atomic Energy (Radiation Protection) Rules 2004 — the synthesizer is one of the engineered controls cited in the licensing dossier, not the licence itself

Operator training and aseptic-intervention qualification records

Sources: EU GMP Annex 1 (2022 revision); EU GMP Annex 11; AERB 2017 Regulatory Requirements; WHO TRS 1025 Annex 2; European Pharmacopoeia.